IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4371
Positioning
Market Dominance
Services
Healthcare
$10M
Milton Chen
Telemedicine shouldn't be another EMR nightmare, and doctors don't need more apps they won't use. That's why we've made it easy for anyone to create a unified telehealth experience that's as simple and accessible as shopping online. Telehealth improves care outcomes, lowers costs, increases access, and alleviates clinician shortages. We are committed to innovating technology that allows our partners to harness the possibilities of telehealth and to progress our mission of making telehealth an everyday experience.
Headcount
—
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = VSEE ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$VSEE VSEE HEALTH, INC. | 32 | 35 | 54 | 7 | - | 2.2x | 996.8% | -324.9% | 59.5% | -477.8% | -452.8% | 132.6% | 0.0% | - | $10M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
VSEE HEALTH, INC. (VSEE) receives a "Avoid" rating with a composite score of 32.1/100. It ranks #4371 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Milton Chen
Chief Executive Officer
35
25
33
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for VSEE
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for VSEE.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 35 | 24 | +11ALPHA |
| MOMENTUM | 7 | 3 | +4NEUTRAL |
| VALUATION | 54 | 58 | -4NEUTRAL |
| INVESTMENT | 25 | 16 | +9ALPHA |
| STABILITY | 33 | 26 | +7ALPHA |
| SHORT INT | 51 | 55 | -4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -54.8% vs WACC 11.2% (spread -66.0%)
GM 59% vs sector 60%, OM -478% vs sector 4%
Capital turnover 1.34x
Rev growth 133%, 3yr history
Interest coverage -2.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags VSEE HEALTH, INC. with an Avoid rating, assigning a composite score of 32.1/100 and 1 out of 5 stars. Ranked #4371 of 7,333 stocks, VSEE falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
VSEE's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 996.8% (sector avg: 5.3%), gross margins of 59.5% (sector avg: 59.6%), net margins of -452.8% (sector avg: 2.3%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
VSEE's value score of 54/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include an EV/EBITDA of 2.21x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
VSEE HEALTH, INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 132.6% vs. a sector average of 7.8% and a return on assets of -324.9% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
VSEE HEALTH, INC. is experiencing notably weak momentum with a score of just 7/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 132.6% year-over-year, while a beta of 0.90 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
VSEE's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.90. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 51/100 for VSEE suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $10M market cap (micro-cap), VSEE HEALTH, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
VSEE HEALTH, INC. is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #4371 of 7,333 overall (40th percentile). Key comparisons include ROE of 996.8% exceeding the 5.3% sector median and operating margins of -477.8% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While VSEE currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (7) would have the largest impact on the composite score.
EV/EBITDA 81% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 18672% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin IN LINE WITH SECTOR BENCHMARKS
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate VSEE HEALTH, INC. (VSEE) as Avoid with a composite score of 32.1/100 at a current price of $0.34. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (54th percentile) and quality (35th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (7th percentile) and investment (25th percentile) tempers our overall conviction. We assign a No Moat rating (30/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
VSEE HEALTH, INC. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.1/100 places it at rank #4371 in our full 7,333-stock universe. At $10M in market capitalization, VSEE HEALTH, INC. is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 133%, though momentum at the 7th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 59% (-0.1pp vs sector) narrow to operating margins of -478% (-481.3pp vs sector) and net margins of -452.8%, yielding a gross-to-net conversion rate of -761%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.34, VSEE HEALTH, INC. is trading near fair value based on current fundamentals. Our value factor score of 54/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at EV/EBITDA of 2.2x (discounted to peers), P/S of 1.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 59% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 996.8% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 133% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 32.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -452.8% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to VSEE HEALTH, INC.. Key risk factors include current negative profitability (net margin -452.8%), below-average price stability (33th percentile), weak quality scores (35th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -452.8%); below-average price stability (33th percentile); weak quality scores (35th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 33th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 59% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate VSEE HEALTH, INC.'s capital allocation as Poor. Key concerns include negative profitability, weak asset returns (ROA -324.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — VSEE HEALTH, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, VSEE HEALTH, INC. receives a Avoid rating with a composite score of 32.1/100 (rank #4371 of 7,333). Our quantitative framework assigns a No Moat (30/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on VSEE HEALTH, INC. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign VSEE HEALTH, INC. a meaningful economic moat, scoring 30/100 on our composite assessment. The ROIC-WACC spread of -66.0% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 13/20.
The strongest moat sources are growth durability (13/20) and margin superiority (9/20). Rev growth 133%, 3yr history. GM 59% vs sector 60%, OM -478% vs sector 4%. These pillars form the core of VSEE HEALTH, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and financial resilience (2.5/20). ROIC -54.8% vs WACC 11.2% (spread -66.0%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect VSEE HEALTH, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 59% providing a solid profitability foundation, robust top-line growth of 133% expanding the revenue base, returns on equity of 996.8% driving shareholder value creation. The margin cascade from 59% gross to -478% operating to -452.8% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 59%, operating margins of -478%, net margins of -452.8%. Return metrics include ROE of 996.8% and ROA of -324.9%. Relative to the Services sector, gross margins are 0.1 percentage points below the sector median of 60%, and ROE of 996.8% compares to a sector median of 5.3%.
The balance sheet reflects revenue growth of 133%. Overall balance sheet health is adequate for the current business environment.
Weak momentum (7th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (35th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
SAN JOSE, CA / ACCESS Newswire / February 5, 2026 / VSEE Health, Inc. (NASDAQ:VSEE), a provider of AI-enabled telehealth and enterprise virtual care solutions, today announced a strategic managed services partnership with GoMyRx, a digital prescription ...
Creating a scalable, AI‑native Virtual ICU platform that drives new recurring revenue and enterprise value. SAN JOSE, CALIFORNIA / ACCESS Newswire / January 29, 2026 / VSee Health, Inc.(Nasdaq:VSEE), a leader in enterprise telehealth and AI-powered ...

VSee Health, a telehealth service provider, has announced the launch of a new program in collaboration with the United States Federal Bureau of Prisons to deliver outpatient specialty medical services to inmates across several federal prisons.
Above 50MA
37.18%
Net New Highs
+51081